TG Therapeutics, Inc. (TGTX) has been one of the stronger performers in the biotech space, with the stock more than doubling off its 52-week low. That rally has pushed shares into the mid-$50s and prompted a natural question among investors: can the stock keep climbing toward $75? The level carries real significance because it aligns with published analyst targets and sits just above the consensus average, making it a realistic but still demanding objective rather than an arbitrary round number.
TG Therapeutics is a commercial-stage biopharmaceutical company focused on B-cell-mediated diseases. Its growth engine is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved for adults with relapsing forms of multiple sclerosis (RMS). The company reported second-quarter 2026 revenue of approximately $240 million, up roughly 70% year over year, with U.S. BRIUMVI net product sales of about $228 million. Management has raised its full-year 2026 guidance, now targeting roughly $890 million to $905 million in U.S. BRIUMVI sales and about $950 million worldwide.
At its most recent close, TGTX traded near $56, below its 52-week high of roughly $59.30 but far above its 52-week low near $25. The company carries a market capitalization around $8 billion and has shifted decisively into profitability, supported by a net margin above 50% in recent periods. A high beta near 1.6 underscores that this remains a volatile, momentum-sensitive name, meaning the path to $75 is unlikely to be a straight line.
Several catalysts could support a move toward $75. First, BRIUMVI has continued to take share in the MS market with a differentiated dosing schedule, and sustained double-digit sales growth would reinforce the revenue trajectory. Second, the company has completed enrollment in a late-stage trial of a subcutaneous (under-the-skin) version of BRIUMVI, with data expected in late 2026 or early 2027. A positive readout could meaningfully expand the addressable patient population by enabling self-administration. Third, TG Therapeutics is testing BRIUMVI in additional indications, including myasthenia gravis, which could diversify revenue beyond MS.
Balance-sheet strength provides further support. The company held roughly $612 million in cash at midyear and has been actively repurchasing shares, which can cushion downside and signal management confidence in the underlying business.
The primary obstacle is concentration risk: BRIUMVI accounts for nearly all of the company's revenue. A slowdown in MS prescription growth, pricing pressure, or a shift in competitive dynamics could quickly pressure the valuation. The MS market is crowded, with established anti-CD20 therapies and emerging oral and injectable options from large competitors such as Novartis (NVS) vying for share.
Execution risk on the subcutaneous program is another concern. A disappointing or delayed readout would remove a key driver of the bull thesis. Finally, biotech names with elevated short interest and high volatility can experience sharp drawdowns even when fundamentals are intact.
Wall Street's view on TGTX is unusually divided. The consensus rating remains a Buy, with average 12-month price targets clustering between roughly $63 and $70. Recent individual targets illustrate the spread: B. Riley at $86, Jefferies at $83, H.C. Wainwright at $78, TD Cowen at $75, and JPMorgan at $72, contrasted with a Bank of America target near $21 carrying an underperform rating. Notably, the $75 objective already exists on the Street, and several firms sit above it, suggesting the level is achievable under an optimistic-but-not-extreme scenario. However, the $20-to-$86 range underscores that bearish analysts see meaningful downside if growth assumptions fail to materialize.
From a technical perspective, the stock's prior 52-week high near $59 represents the first meaningful resistance level that must be cleared before any sustained push toward $75. On the downside, the 200-day moving average, which has tracked near the $40 area, has historically served as longer-term trend support during the stock's ascent. The $75 target sits well above recent trading ranges, meaning it would require a decisive breakout and fresh institutional accumulation rather than incremental drift.
For traders seeking a data-driven edge in volatile names like TGTX, Tickeron's AI Daily Buy/Sell Signals offer a systematic way to monitor shifting conditions. The product uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market behavior, technical patterns, and AI-driven analysis. These signals can help traders identify emerging opportunities, track existing positions, and spot turning points in market trends more efficiently than manual chart review alone. Consider exploring the AI Daily Buy/Sell Signals to see how automated analysis might complement your own research.
A move to $75 for TG Therapeutics is realistic but far from guaranteed. The strongest case rests on continued BRIUMVI momentum, a successful subcutaneous readout, and the company's improving profitability and cash position. The biggest risks are single-product concentration, a crowded competitive field, and the wide divergence between bullish and bearish analyst targets. Investors monitoring this name should focus on quarterly BRIUMVI sales trends, any updates to 2026 guidance, the subcutaneous trial data timeline, and the stock's ability to clear its prior high near $59. As with any high-beta biotech, the journey to $75 would likely require both strong execution and a favorable market environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, TGTX has been loosely correlated with ARQT. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TGTX jumps, then ARQT could also see price increases.
| Ticker / NAME | Correlation To TGTX | 1D Price Change % | ||
|---|---|---|---|---|
| TGTX | 100% | -2.71% | ||
| ARQT - TGTX | 40% Loosely correlated | +2.16% | ||
| ARRY - TGTX | 36% Loosely correlated | +1.54% | ||
| CLLS - TGTX | 36% Loosely correlated | +1.64% | ||
| KRYS - TGTX | 36% Loosely correlated | +0.42% | ||
| IMCR - TGTX | 36% Loosely correlated | -2.92% | ||
More | ||||